Combination reagent and system for detecting acute myeloid leukemia cells

A leukemia cell and acute myeloid technology, applied in the field of combined reagents and systems for detecting acute myeloid leukemia cells, can solve problems such as low sensitivity, easy missed diagnosis, and no unified standard, meet the requirements of reducing the level of professional knowledge, and detect quickly , covering a wide range of effects

Active Publication Date: 2022-05-06
GUANGZHOU KINGMED DIAGNOSTICS CENT
View PDF10 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Based on this, it is necessary to provide a combined reagent and system for detecting acute myeloid leukemia cells in view of the problems of low sensitivity, no uniform standard, and easy missed diagnosis in the existing detection methods. Rapid and highly sensitive detection of AML-MRD by multiparameter flow cytometry

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination reagent and system for detecting acute myeloid leukemia cells
  • Combination reagent and system for detecting acute myeloid leukemia cells
  • Combination reagent and system for detecting acute myeloid leukemia cells

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0081] A combined reagent for detecting acute myeloid leukemia cells, specifically as follows:

[0082] Combination 1: CD38 / CD13 / CD34 / CD117 / CD33 / CD19 / HLA-DR / CD45;

[0083] Combination 2: CD38 / CD64 / CD34 / CD123 / CD56 / CD14 / HLA-DR / CD45;

[0084] Combination 3: CD38 / CD7 / CD34 / CD5 / CD11b / CD15 / CD45.

[0085] The fluorescent labels and dosages of relevant monoclonal antibodies in the above combinations are shown in the table below.

[0086] Table 2. The dosage of each monoclonal antibody

[0087]

[0088] Note: The concentration gradient of the commercially available antibodies was verified to determine the optimal dosage, so the above-mentioned monoclonal antibodies were loaded into flow tubes numbered 1, 2, and 3, respectively.

Embodiment 2

[0090] A system for detecting acute myeloid leukemia cells, comprising: a detection module, a data acquisition module and a data analysis module.

[0091] The detection module performs flow cytometry detection on the cells to be tested;

[0092] The data acquisition module acquires the flow cytometry detection result data of the cells to be tested stained with the combined reagent described in Example 1;

[0093] The data analysis module analyzes the above acquired data, and determines whether the cells to be tested are tumor cells according to predetermined criteria.

[0094] The specific workflow of using the above system is as follows:

[0095] 1. Prepare reagents.

[0096] The combination reagents described in Example 1 were prepared.

[0097] 2. Sample processing.

[0098] The sample source of the cells to be tested can be bone marrow, peripheral blood, pleural effusion, ascites, etc., and the concentration is adjusted to 1×10 according to the number of cells. 6 -5×1...

Embodiment 3

[0125] The system for detecting acute myeloid leukemia cells in Example 2 was used to detect minimal residues of acute myeloid leukemia, and 40 daily samples were randomly selected for detection. Compared with the gold standard of bone marrow smear morphology detection, there were 0 cases of false positive results , 0 cases of false negatives, confirming that the above system can detect AML-MRD comprehensively, quickly and with high sensitivity through multi-parameter flow cytometry analysis.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a combined reagent and system for detecting acute myeloid leukemia cells, belonging to the technical field of medicine. The combination reagent includes at least one of the following antibody combinations: antibody combination 1, including CD38, CD13, CD34, CD117, CD33, CD19, HLA‑DR and CD45 antibodies; antibody combination 2, including CD38, CD64, CD34, CD123 , CD56, CD14, HLA‑DR, and CD45 antibodies; antibody panel 3: includes CD38, CD7, CD34, CD5, CD11b, CD15, and CD45 antibodies. The antibody combination of the present invention covers the expression markers of three lineages of granulocystosis, monocystosis and lymphoma, and with the establishment of a normal antibody expression pattern, it can identify tumor cells to the greatest extent. Moreover, a large amount of experimental data shows that there is no problem of mutual inhibition of expression among the antibodies in each combination of the present invention. AML‑MRD can be detected comprehensively, quickly and with high sensitivity through multiparameter flow cytometry analysis.

Description

technical field [0001] The invention relates to the field of medical technology, in particular to a combined reagent and system for detecting acute myeloid leukemia cells. Background technique [0002] Acute myeloid leukemia (AML) is a malignant disease of myeloid hematopoietic stem / progenitor cells. It is mainly characterized by abnormal proliferation of primitive and immature myeloid cells in bone marrow and peripheral blood. The clinical manifestations are anemia, hemorrhage, infection and fever, visceral infiltration, and metabolic abnormalities. Most cases are acute and severe, and the prognosis is dangerous. If not treated in time Often life-threatening. The presence of minimal residual disease (MRD) is a high risk factor for relapse in patients undergoing chemotherapy induction and / or bone marrow reconstitution. Clinically, according to the level of MRD, it is necessary to adjust the treatment plan and adjust the dosage to achieve the purpose of cure. Therefore, wh...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): G01N33/574G01N33/577G01N33/533
CPCG01N33/533G01N33/57426G01N33/577
Inventor 潘建华张静文何凯琴郑倩李明敏郭鸣琪
Owner GUANGZHOU KINGMED DIAGNOSTICS CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap